The table is a review of notable updates that occurred in February 2025 for investigational products in development.

Latigo Biotherapeutics has whipped together a $150 million series B fundraising round to advance a pipeline of non-opioid ...

Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

Rentosertib is designed to treat IPF by targeting Traf2- and NCK-interacting kinase (TNIK), a serine/threonine kinase whose activation plays a crucial role in cellular processes that include signal ...

One of the most highly anticipated FDA decisions this month is for Alnylam Pharmaceuticals, which is seeking to expand the ...

We believe Genmab is in solid financial health. At the end of 2024, Genmab held DKK 9.9 billion in cash and cash equivalents. After turning profitable in 2013, the company has steadily increased its ...

Novavax (NVAX) has recently seen a decrease in stock value, dropping after announcing Q4 results that missed revenue expectations. The company ...

Four years after Sanofi shelled out $125 million for global rights to Biond Biologic | The company is handing back the tumor candidate it snapped up in 2021 after initiating a phase 2 trial of the ...

Immunology is a rapidly advancing field with significant potential for growth, especially in the realm of biotech and pharmaceutical companies.

Gain insights into Recursion Pharmaceuticals' Q4 2024 earnings call. Discover clinical advancements, key partnerships, and strategic plans for 2025.